Corbus Pharmaceuticals Holdings, Inc. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of 0.20% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-03-09
- Corbus Pharmaceuticals Holdings, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2025 was 0.20%, a 71.43% decline from fiscal 2024.
- Corbus Pharmaceuticals Holdings, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was 0.70%.
- Corbus Pharmaceuticals Holdings, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was -11.09%.
- Corbus Pharmaceuticals Holdings, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was -5.99%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | 0.20% 10-K · filed 2026-03-09 | |
| 2024-12-31 | 0.70% 10-K · filed 2026-03-09 | -0.52% 10-K · filed 2025-03-11 |
| 2023-12-31 | -11.09% 10-K · filed 2025-03-11 | |
| 2022-12-31 | -5.99% 10-K · filed 2024-03-12 | |
| 2021-12-31 | -17.37% 10-K · filed 2023-03-07 | |
| 2020-12-31 | -8.12% 10-K · filed 2022-03-08 | |
| 2019-12-31 | 0.45% 10-K · filed 2021-03-15 | |
| 2018-12-31 | 1.14% 10-K · filed 2020-03-16 | |
| 2017-12-31 | 0.60% 10-K · filed 2019-03-12 | |
| 2016-12-31 | -0.13% 10-K · filed 2018-03-12 | |
| 2015-12-31 | 0.04% 10-K · filed 2018-03-12 | |
| 2014-12-31 | 0.21% 10-K · filed 2016-03-28 | |
| 2013-12-31 | 7.47% 10-K · filed 2015-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |